The present invention discloses an extended release multi-particulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

Provided herein are methods and compositions, including synergistic combinations, for the treatment of tuberculosis.

Provided herein are methods and compositions, including synergistic combinations, for the treatment of tuberculosis.

Provided herein are methods and compositions, including synergistic combinations, for the treatment of tuberculosis.

Disclosed is a pharmaceutical unit dosage composition including a plurality of enteric coated micro pellets. Each enteric coated micro pellet includes a core bead, an optional first sealing layer, an API layer including a Compound (I) having the following structure or a pharmaceutically acceptable salt thereof, an optional second sealing layer, and an enteric coating layer. Also disclosed is a method for the treatment and prophylaxis of RSV diseases including providing a Compound (I) and administering to a patient in need thereof a therapeutically effective amount of the Compound (I) so that t½ of the Compound (I) is about 6 to 13 hours.

##STR00001##

Disclosed is a pharmaceutical unit dosage composition including a plurality of enteric coated micro pellets. Each enteric coated micro pellet includes a core bead, an optional first sealing layer, an API layer including a Compound (I) having the following structure or a pharmaceutically acceptable salt thereof, an optional second sealing layer, and an enteric coating layer. Also disclosed is a method for the treatment and prophylaxis of RSV diseases including providing a Compound (I) and administering to a patient in need thereof a therapeutically effective amount of the Compound (I) so that t½ of the Compound (I) is about 6 to 13 hours.

##STR00001##

The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.

The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.

The invention relates to an internal cyclic sulphiamidine amide-aryl amide compound and a use thereof for treating hepatitis B. Specifically, disclosed is a compound that may act as an HBV replication inhibitor and that has a structure represented by chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvent thereof. See the description for detailed definitions of each group. The present invention also relates to a pharmaceutical composition containing the compound and a use thereof for treating hepatitis B.

##STR00001##

A portable transdermal administration patch apparatus comprises a communication control device and a pharmaceutical device which is fixed to and arranged at a lower end of the communication control device and electrically connected to the communication control device. The communication control device is formed of a micro-battery, a wireless control device and a micro-controller which are electrically connected. The preparation of the patch apparatus is achieved by: the preparation of medicinal patches and non-medicinal patches, the mounting of electrodes, interfacing with a micro-controller, and the communication control system, and starting administration. The transdermal apparatus is wearable and can be remotely controlled, and is convenient for administration, in particular, for the situations of daily administration for elderly patients with chronic illness and when there are a larger number of admitted inpatients, where a nurse can pre-set the administration time and dose, thus saving time and efforts of medical staff.